Method for treating effects of sleep deprivation and jet lag with NADPH and NADPH

• US 20030021772A1
• Filed: 06/29/2001
• Published: 01/30/2003
• Est. Priority Date: 06/29/2001
• Status: Abandoned Application

• Current Assignee: Birkmayer Pharmaceuticals, Inc.
• Original Assignee: Birkmayer Pharmaceuticals, Inc.
• Inventors: Birkmayer, Joerg G. D.
• Application Number:
  US09/896,209
• Publication Number:
  US 20030021772A1
• Time in Patent Office: Days
• US Class Current: 424/94.1
• CPC Class Codes: A61K 31/711 Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links

Abstract

A method for alleviating the symptoms of sleep deprivation or jet lag wherein the reduced form of nicotinamide adenine dinucleotide (NADH) or the reduced form of nicotinamide adenine dinucleotide phosphate (NADPH) or physiologically compatible salts or derivatives of NADH and/or NADPH are administered to a human being suffering from the effects. Human beings so treated exhibit an abatement of these effects, such as, for example, decreased attentiveness, decreased ability to concentrate, decreased reaction time, decreased alertness, and decreased productivity and efficiency.

Claims

1. A method for alleviating the effects of sleep deprivation in a human being, comprising administering to a human being exhibiting the effects of sleep deprivation an amount of NADH or NADPH or a physiologically compatible salt of NADH or NADPH which is effective to reduce or eliminate said effects of sleep deprivation.

2. The method of claim 1 wherein the NADH or NADPH or physiologically compatible salt of NADH or NADPH is administered intravenously.

3. The method of claim 1 wherein the NADH or NADPH or physiologically compatible salt of NADH or NADPH is administered orally.

4. The method of claim 1 wherein the NADH or NADPH or physiologically compatible salt of NADH or NADPH is administered sublingually.

5. The method of claim 1 wherein the NADH or NADPH or physiologically compatible salt of NADH or NADPH is administered rectally.

6. The method of claim 1 wherein the NADH or NADPH or physiologically compatible salt of NADH or NADPH is administered to a nasal passage of the human being to result in absorption of the NADH or NADPH or physiologically compatible salt of NADH or NADPH into the mucosa of the nose.

7. The method of claim 1 wherein the NADH or NADPH or physiologically compatible salt of NADH or NADPH is administered in a dose of from 1 mg to 20 mg.

8. The method of claim 1 wherein the NADH is administered in a dose of from 5 mg to 10 mg.

9. The method of claim 1 wherein the NADPH is administered in a dose of from 1 mg to 5 mg.

10. The method of claim 8 wherein said dose is administered every 24 hours.

11. The method of claim 1 wherein the NADH or NADPH or physiologically compatible salt of NADH or NADPH is administered in combination with coenzyme Q10, L-carnitine or L-glutathion.

12. A method for alleviating the effects of jet lag in a human being, comprising administering to a human being exhibiting the effects of jet lag an amount of NADH or NADPH or a physiologically compatible salt of NADH or NADPH which is effective to reduce or eliminate said effects of jet lag.

13. The method of claim 12 wherein the NADH or NADPH or physiologically compatible salt of NADH or NADPH is administered intravenously.

14. The method of claim 12 wherein the NADH or NADPH or physiologically compatible salt of NADH or NADPH is administered orally.

15. The method of claim 12 wherein the NADH or NADPH or physiologically compatible salt of NADH or NADPH is administered sublingually.

16. The method of claim 12 wherein the NADH or NADPH or physiologically compatible salt of NADH or NADPH is administered rectally.

17. The method of claim 12 wherein the NADH or NADPH or physiologically compatible salt of NADH or NADPH is administered to a nasal passage of the human being to result in absorption of the NADH or NADPH or physiologically compatible salt of NADH or NADPH into the mucosa of the nose.

18. The method of claim 12 wherein the NADH or NADPH or physiologically compatible salt of NADH or NADPH is administered in a dose of from 1 mg to 20 mg.

19. The method of claim 12 wherein the NADH is administered in a dose of from 5 mg to 10 mg.

20. The method of claim 12 wherein the NADPH is administered in a dose of from 1 mg to 5 mg.

21. The method of claim 19 wherein said dose is administered every 24 hours.

22. The method of claim 12 wherein the NADH or NADPH or physiologically compatible salt of NADH or NADPH is administered in combination with coenzyme Q10, L-carnitine or L-glutathion.

23. A method for enhancing attentiveness, alertness, concentration or reaction time in a human being, comprising administering to a human being an amount of NADH or NADPH or a physiologically compatible salt of NADH or NADPH which is effective to improve attentiveness, alertness, concentration or reaction time.

24. The method of claim 23 wherein the NADH or NADPH or physiologically compatible salt of NADH or NADPH is administered intravenously.

25. The method of claim 23 wherein the NADH or NADPH or physiologically compatible salt of NADH or NADPH is administered orally.

26. The method of claim 23 wherein the NADH or NADPH or physiologically compatible salt of NADH or NADPH is administered sublingually.

27. The method of claim 23 wherein the NADH or NADPH or physiologically compatible salt of NADH or NADPH is administered rectally.

28. The method of claim 23 wherein the NADH or NADPH or physiologically compatible salt of NADH or NADPH is administered to a nasal passage of the human being to result in absorption of the NADH or NADPH or physiologically compatible salt of NADH or NADPH into the mucosa of the nose.

29. The method of claim 23 wherein the NADH or NADPH or physiologically compatible salt of NADH or NADPH is administered in a dose of from 1 mg to 20 mg.

30. The method of claim 23 wherein the NADH is administered in a dose of from 5 mg to 10 mg.

31. The method of claim 23 wherein the NADPH is administered in a dose of from 1 mg to 5 mg.

32. The method of claim 30 wherein said dose is administered every 24 hours.

33. The method of claim 23 wherein the NADH or NADPH or physiologically compatible salt of NADH or NADPH is administered in combination with coenzyme Q10, L-carnitine or L-glutathion.